Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting


Results from 213 patient study demonstrates use of urinary ctDNA as a stand-alone test for the highly sensitive detection of EGFR T790M mutations for therapy selection



SAN DIEGO - Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, announced today that diagnostic performance results using the Company's Precision Cancer Monitoring® platform to detect and monitor EGFR T790M in the urine of non-small cell lung cancer (NSCLC) patients will be the subject of an oral presentation given by Heather Wakelee, M.D., Stanford University Medical Center, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstracts for the ASCO meeting were released last night, and can be viewed at http://abstracts.asco.org/



Presentation Details:



Title: Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients treated with rociletinib



    --  Presenter: Heather Wakelee, M.D., Stanford University Medical Center

    --  Date/Time: Monday, June 6, 2016, 9:57am Central Daylight Time

    --  Oral Abstracts Session: Lung Cancer-Non-Small Cell Metastatic

    --  Location: Arie Crown Theater



About Trovagene, Inc.



Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine.  The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's Precision Cancer Monitoring® platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.



About Trovagene's Precision Cancer Monitoring platform



Trovagene's urine and blood-based EGFR, KRAS and BRAF oncogene mutation assays are now available to healthcare providers for detection and/or monitoring of tumor dynamics in their patients before, during and after treatment. Physicians interested in utilizing these tests should contact Client Services at 888-391-7992. For more information, please visit www.trovagene.com/our-tests.



Source 

Trovagene, Inc.



Web Site: http://www.trovagene.com






Related

All Topics